Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.60 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | PDCD1 | Q15116 | 3/20 | 0.34 |
| ▸ | CD274 | Q9NZQ7 | 3/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | MITF | O75030 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26491390 | 1.00 | KMT2A (0.60) | KMT2AMEN1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL4171725 | 1.00 | KMT2A (0.60) | KMT2AMEN1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL13775047 | 1.00 | KMT2A (0.60) | KMT2AMEN1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL19682309 | 1.00 | KMT2A (0.60) | KMT2AMEN1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL14449225 | 0.90 | KMT2A (0.55) | KMT2AMEN1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL14817721 | 0.90 | KMT2A (0.55) | KMT2AMEN1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL26491387 | 0.90 | KMT2A (0.52) | KMT2AMEN1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL17147996 | 0.90 | KMT2A (0.52) | KMT2AMEN1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL13205045 | 0.90 | KMT2A (0.55) | KMT2AMEN1L3MBTL1ALDH1A1MAPT | |
| SCHEMBL24086072 | 0.89 | KMT2A (0.54) | KMT2AMEN1L3MBTL1ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2004048396-A1 | SPECIFIC ACYLATION OF CARBOHYDRATE HYDROXYLS | DOW GLOBAL TECHNOLOGIES INC. (US) | 2004-06-10 | — | — | WO | disclosed |
| US-20040102617-A1 | Specific acylation of carbohydrate hydroxyls | MOLITOR ERICH J (US) | 2004-05-27 | — | — | US | disclosed |
| US-6723843-B2 | USE OF A 2-SUBSTITUTED-1,3-DIOXOCYCLOALKYL LINKER GROUP TO COUPLE SACCHARIDE GROUPS OF BOTH THE O-GLYCOSIDE AND N-GLYCOSIDE TYPE TO A POLYMER SUPPORT IN A SOLID PHASE SYSTHESIS PROCESS | ALCHEMIA PTY LTD (AU) | 2004-04-20 | — | — | US | disclosed |
| US-6573337-B1 | Dioxocyclohexane compound linker for solid-phase synthesis of oligosaccharides | ALCHEMIA PTY LTD (AU) | 2003-06-03 | — | — | US | disclosed |
| US-20030027925-A1 | Oligosaccharide synthesis | ALCHEMIA PTY LTD | 2003-02-06 | — | — | US | disclosed |
| EP-0923528-B1 | OLIGOSACCHARIDE SYNTHESIS | ALCHEMIA PTY LTD (AU) | 2002-11-06 | — | — | EP | disclosed |
| US-5747463-A | SELECTIN ANTAGONISTS; ANTIINFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-05-05 | — | — | US | disclosed |
| US-5686426-A | Dicarboxymethylated glycolipid derivatives as cell adhesion inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-11-11 | — | — | US | disclosed |
| US-5663151-A | ANTIINFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1997-09-02 | — | — | US | disclosed |
| US-5565433-A | ADMINISTERING IN TREATMENT AND PREVENTION OF INFLAMMATORY DISEASES | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-10-15 | — | — | US | disclosed |
| EP-0719787-A1 | Dicarboxymethylated glycolipid derivatives as cell adhesion inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-07-03 | — | — | EP | disclosed |
| EP-0671407-A2 | Sulfated alpha-glycolipid derivatives as cell adhesion inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-09-13 | — | — | EP | disclosed |
| EP-0671406-A2 | Sulfated beta-glycolipid derivatives as cell adhesion inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 1995-09-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040102617-A1 | Specific acylation of carbohydrate hydroxyls | HSD17B14, FUT6, UGGT1 | KMT2A 2026/4885MEN1 3612/4885L3MBTL1 3740/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.